Lobe Sciences Ltd. announced an exclusive agreement with Clearway Global LLC . In recent preclinical studies, treatment with Lobe's unique platform technology combining N-acetyl cysteine (NAC) with the bio psychedelic psilocybin, showed statistically significant positive results in a model of PTSD when compared to either moiety alone. In association with Clearway the Company plans to develop proprietary new chemical entities (NCEs) that improve upon naturally derived psychedelic molecules which can be unstable as pharmaceutical drugs.

These NCEs are being studied as potentially low dose therapeutics without the psychedelic effect to allow patients to be treated at home or by their family physician.